smithkline beckman corp said and signed final agreement develop and market new cardiovascular medicines discovered boehringer under agreement smithkline said will have responsibility for developing products both partners will market products and abroad initially smithkline said companies will concentrate clinical development and marketing carvedilol which compound treat mild moderate hypertension and angina application for marketing approval carvedilol was submitted west germany last december smithkline said applications expected european markets this year and submission food and drug administration projected for 1990 said work also underway thromboxane receptor antagonists compounds which could useful accelerating disolution blood clots and preventing blod clots from occuring heart attack well arterial diseases company said two these compounds clinical evaluation europe and reuter 